Time to peak serum antibody response to influenza vaccine. 1995

S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
Department of Internal Medicine, Hackensack Medical Center, New Jersey 07601.

The time to the appearance of a peak serum antibody response to influenza virus vaccine is not clearly defined. We compared the most commonly used time intervals described in the literature--4 and 6 weeks after vaccination. We studied 118 elderly patients from three different geographic sites. The 1992 to 1993 trivalent inactivated influenza virus vaccine containing influenza virus A/Beijing/353/89 (H3N2), influenza virus A/Texas/36/91 (H1N1), and influenza virus B/Panama/45/90 was used. No statistically significant differences were found at the 4- and 6-week intervals after vaccination.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D009515 New Jersey State bounded on the north by New York and Pennsylvania, on the east by New York and the Atlantic Ocean, on the south by Delaware Bay, and on the west by Pennsylvania.
D009519 New York City City located at the mouth of the Hudson River, in New York State.
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D009981 Influenza B virus Species of the genus BETAINFLUENZAVIRUS that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed. Betainfluenzavirus influenzae,FLUBV,Human Influenza B Virus,Influenza Viruses Type B,Influenza virus type B,Orthomyxoviruses Type B,Influenza B viruses
D004194 Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown. Diseases
D006386 Hemagglutination Tests Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed) Hemagglutination Test,Test, Hemagglutination,Tests, Hemagglutination
D006389 Hemagglutinins, Viral Specific hemagglutinin subtypes encoded by VIRUSES. Viral Hemagglutinin,Viral Hemagglutinins,Hemagglutinin, Viral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
May 1996, Clinical and diagnostic laboratory immunology,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
July 1997, Clinical and diagnostic laboratory immunology,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
August 1996, Chest,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
February 2001, Immunopharmacology and immunotoxicology,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
March 1958, Journal of the American Medical Association,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
October 1978, Canadian Medical Association journal,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
April 2010, Vaccine,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
January 2012, Vaccine,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
June 1994, Annals of the New York Academy of Sciences,
S Rastogi, and P A Gross, and J Bonelli, and S Dran, and R A Levandowski, and C Russo, and M E Weksler, and D Kaye, and M Levison, and E Abrutyn
January 1994, Clinical and diagnostic virology,
Copied contents to your clipboard!